IMMY买入原因:今天IMMY发的干眼症药物为Restasis的仿制药,RESTASIS 2016年第三季度全球销售额为371.6million, 第四季度全球销售额393.1 million占干眼症市场的80%,现有竞争对手仅有Shire’s idra,占20%的市场。IMMY的仿制药由于是走低价路线,有可...查看全文
TLS美股研究2017-04-09 21:31
回复@panderson: $IMPRIMIS PHARMACEUTICALS INC(IMMY)$ 我们看看。我刚打赏了这条评论 ¥2.88,也推荐给你。//@panderson:回复@TLS美股研究:IMMY值得关注,眼科市场天花板逐渐打开,公司高管参与增发,市值迷你,会是小黑马吗 查看全文
$Imprimis Pharmaceuticals, Inc.(IMMY)$ 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2018-03-08 AccNo: 0001493152-18-003095 Size: 7 MB 网页链接
$Imprimis Pharmaceuticals, Inc.(IMMY)$ 内部交易: 2018-02-01,Chief Commercial Officer,SAHAREK JOHN P. ,期权,30000普通股, $1.83
$Imprimis Pharmaceuticals, Inc.(IMMY)$ 内部交易: 2018-02-01,CFO,BOLL ANDREW R. ,期权,30000普通股, $1.83
$Imprimis Pharmaceuticals, Inc.(IMMY)$ 8-K - Current report Filed: 2018-01-09 AccNo: 0001493152-18-000337 Size: 3 MBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$Imprimis Pharmaceuticals, Inc.(IMMY)$ 8-K - Current report Filed: 2017-11-14 AccNo: 0001493152-17-013203 Size: 124 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Imprimis Pharmaceuticals, Inc.(IMMY)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2017-11-14 AccNo: 0001493152-17-013187 Size: 4 MB 网页链接
$Imprimis Pharmaceuticals, Inc.(IMMY)$ 8-K - Current report Filed: 2017-11-14 AccNo: 0001493152-17-013203 Size: 124 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Imprimis Pharmaceuticals, Inc.(IMMY)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2017-11-14 AccNo: 0001493152-17-013187 Size: 4 MB 网页链接
$Imprimis Pharmaceuticals, Inc.(IMMY)$ 8-K - Current report Filed: 2017-10-24 AccNo: 0001493152-17-011937 Size: 6 MBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$Imprimis Pharmaceuticals, Inc.(IMMY)$ 8-K - Current report Filed: 2017-09-21 AccNo: 0001493152-17-010798 Size: 57 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接